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1. Introduction
Migraine is a disabling disorder with a life time prevalence 
of 13-33% (Launer et al., 1999). Several studies suggest 
that migraine can be considered as a complex neurogenic 
inflammatory disorder (Monteith and Goadsby, 2011; 
Waeber and Moskowitz, 2005; Wang et al., 2010), but the 
pathophysiology is still not fully understood (Samsam 
et al., 2010). Associations were found between migraine 
and gastrointestinal disorders including irritable bowel 
syndrome, inflammatory bowel disease and celiac disease 
(Van Hemert et al., 2014). These associations have been 
found in two directions: migraine patients have more often 
gastrointestinal disorders compared with healthy controls 
and patients with gastrointestinal disorders more often 
suffer from migraine compared to control groups. These 
associations could be explained by an increased intestinal 
permeability, which could be a cause or consequence of these 
gastrointestinal disorders (Duerksen et al., 2005; Kerckhoffs 
et al., 2010; Piche et al., 2009; Salim and Soderholm, 2011). 
Increased intestinal permeability can allow leakage of 
undigested food particles and bacterial components like 
lipopolysaccharides into the bloodstream; the leaky gut 
hypothesis (Parlesak et al., 2000). These endotoxins can 
trigger a response provoking migraine (Covelli et al., 2003; 
Mennigen and Bruewer, 2009). Consequently, diminishing 
gastrointestinal permeability may reduce the frequency 
and/or the intensity of migraine attacks.
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Abstract
Migraine prevalence is associated with gastrointestinal disorders. Possible underlying mechanisms could be increased 
gut permeability and inflammation. Probiotics may decrease intestinal permeability as well as inflammation, and 
therefore may reduce the frequency and/or intensity of migraine attacks. Therefore we assessed feasibility, possible 
clinical efficacy, and adverse reactions of probiotic treatment in migraine patients. 29 migraine patients took 2 g/d 
of a probiotic food supplement (Ecologic®Barrier, 2.5×109 cfu/g) during 12 weeks. Participants recorded frequency 
and intensity of migraine in a headache diary and completed the Migraine Disability Assessment Scale (MIDAS) and 
Henry Ford Hospital Headache Disability Inventory (HDI) at baseline and after 12 weeks of treatment. Compliance 
was measured every 4 weeks by counting the remaining sachets with probiotics. The study was completed by 27/29 
(93%) patients who took 95% of the supplements. Obstipation was reported by 4 patients during the first 2 weeks of 
treatment only. The mean±standard deviation (SD) number of migraine days/month decreased significantly from 
6.7±2.4 at baseline to 5.1±2.2 (P=0.008) in week 5-8 and 5.2±2.4 in week 9-12 (P=0.001). The mean±SD intensity of 
migraine decreased significantly from 6.3±1.5 at baseline to 5.5±1.9 after treatment (P=0.005). The MIDAS score 
improved from 24.8±25.5 to 16.6±13.5 (P=0.031). However, the mean HDI did not change significantly. In conclusion, 
probiotics may decrease migraine supporting a possible role for the intestine in migraine management. Feasibility 
and lack of adverse reactions justify further placebo-controlled studies.
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Probiotics are living microorganisms which, when 
administered in adequate amounts, confer a health 
benefit to the host (FAO/WHO, 2001; Hill et al., 2014). 
Probiotics have been proven in vitro as well as in vivo to 
prevent damaging of the epithelial barrier (Ohland and 
Macnaughton, 2010). Furthermore, they are able to improve 
the epithelial barrier in several ways, depending on the 
used bacterial strain (Anderson et al., 2010; Miyauchi et 
al., 2012). They can increase the mucus production of the 
goblet cells, they are able to stabilise the tight junctions 
between the epithelial cells and they can enhance IgA 
production (Ohland and Macnaughton, 2010). Probiotics 
can also have an indirect effect on the resident microbiota. 
For example, some probiotic bacterial strains directly kill 
pathogenic bacteria by secreting antimicrobial factors 
(Liévin et al., 2000). They can also compete with pathogens 
for binding sites on the epithelial cells (Neeser et al., 2000), 
which improves the barrier function.
So far, no clinical randomised controlled trials studying the 
influence of probiotics on migraine have been published. An 
uncontrolled study with a combination of various bacterial 
strains (Lactobacillus acidophilus DDS-1, Lactobacillus 
bulgaricus, Enterococcus faecium and Bifidobacterium 
bifidum, strain numbers for the latter were not indicated 
in the publication) and vitamins, minerals, micronutrients, 
and herbs in 40 migraine patients demonstrated that 60% 
of the migraine patients experienced almost total relief 
from migraine attacks (Sensenig et al., 2001). It remains 
unknown if this improvement was due to placebo effects, 
one or more bacteria, or due to the other nutrients.
To study the possible association between migraine, 
intestinal permeability and probiotics and to assess 
therapeutic consequences, large scale clinical studies with 
probiotics in migraine patients are needed. We started with 
an open-label pilot study with a multispecies probiotic 
product to assess feasibility, possible adverse reactions, and 
a first impression of clinical efficacy in migraine patients.
2. Materials and methods
Subjects
Participants were recruited via the recruitment database of 
Wageningen University, advertisements on the staff website 
of hospital ‘Gelderse Valei’ in Ede, and by advertisements 
on notice boards at Wageningen University. Subjects 
willing to participate were screened by means of a medical 
screening questionnaire. Subjects fulfilling the International 
Headache Classification (ICHD-II) criteria, aged ≥18 years, 
and who had at least 4 migraine attacks per month with a 
stable pattern were eligible for the study. Exclusion criteria 
were chronic headache, medication-dependent headache, 
or other types of headaches, the use of antibiotics up to 
two months before the start of the study and the use of 
probiotics, other than used during this study during or up 
to two weeks before the start of the treatment period. All 
participants gave their written informed consent. The pilot 
study was approved by the Medical Ethical Committee of 
Wageningen University (dossier 11/44) and was performed 
according to the principles of the Declaration of Helsinki.
Study design
Between February and June 2012 participants received 2 
g of the multispecies probiotic product Ecologic®Barrier 
(Winclove Probiotics, Amsterdam, the Netherlands) daily 
for 12 weeks. The product (2.5×109 cfu/gram) contains the 
following bacterial strains: Bifidobacterium bifidum W23, 
Bifidobacterium lactis W52, Lactobacillus acidophilus 
W37, Lactobacillus brevis W63, Lactobacillus casei W56, 
Lactobacillus salivarius W24, Lactococcus lactis W19 and 
Lactococcus lactis W58. All these strains have been used 
before in different combinations in clinical trials showing a 
health benefit (Koning et al., 2008; Lamprecht et al., 2012; 
Niers et al., 2009; Persborn et al., 2013, Lamprecht, 2012). 
Compliance was measured every four weeks by counting 
the remaining sachets with probiotics.
Baseline number of migraine days per month were based 
on recall of the participants. At baseline and after 12 weeks 
of ingestion of the probiotics, the participants completed 
two headache questionnaires: The Migraine Disability 
Assessment Scale (MIDAS) and the Henry Ford Hospital 
Headache Disability Inventory (HDI,) to assess intensity of 
the migraine (Jacobson et al., 1994; Stewart et al., 1999). The 
MIDAS questionnaire assesses missed days of activity, but 
also days in which the productivity was reduced by at least 
half during the last three months. The HDI questionnaire 
focussed on the functional and emotional feelings about 
having headaches.
During the study period, the participants completed a 
headache diary daily. In this diary, frequency and intensity 
(10-point Likert scale) of migraine attacks, used medication 
and gastrointestinal complaints were recorded. The diaries 
were handed out, discussed and collected every 4 weeks.
Statistical analysis
We performed a sample size calculation based on previous 
drug trials aimed at reducing the number of days with 
migraine (Bensenor et al., 2001; Diener et al., 2004; 
Pfaffenrath et al., 2002). From these studies we derived 
the standard deviation (SD) of the effect to be within 1.3 
and 2.1 days. Using these estimates of the SD in the formula 
n=7.9 × (SD/D)2 (D = the expected change between baseline 
and 12 weeks), it was calculated that for an effect of 1 days 
(reduction in migraine days/month) between 15 and 35 of 
patients were needed (using a confidence level of 5% and 
a power of 80%).
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The difference of the mean number of migraine days between 
the four week periods and the difference of outcomes of the 
questionnaires were analysed using the paired samples t-test 
as these data were normally distributed. To compare the 
data of the migraine patients with bowel complaints with 
those of the migraine patients without bowel complaints, an 
independent samples t-test was used. IBM SPSS Statistics 
(version 19; Armonk, NY, USA) was used to analyse data. 
Data are given as mean±SD and P-values of <0.05 were 
considered as significant in all analyses.
3. Results
Baseline data
In total, 37 patients (3 males, 34 females) showed interest 
in participation in the study, of which 29 persons met the 
in- and exclusion criteria. From the initial 29 participants, 
1 male and 26 females (mean age: 41.8±14.7 years; range: 
20-64) completed the study. The other two 2 participants 
(1 male, 1 female) dropped out; one for unknown 
reasons and one because he/she did not like the taste of 
the probiotics. Mean duration of migraine was 19±14.2 
years (range: 1-60 years); 7 of the 27 (26%) participants 
experienced auras during their migraine attacks. In 14 
of the 26 (54%) female participants, menstrual periods 
were accompanied by migraine. Regular gastrointestinal 
complaints, such as obstipation and diarrhoea, were 
reported by 19 (70%) of the participants. Of all sachets 
with probiotics, 95% were returned empty. Over each period 
of 4 weeks, 52% of the participants took all sachets, 44% of 
the participants missed 1-5 of the 28 sachets and 4% missed 
more than 5 sachets. Four participants noticed constipation 
in the first two weeks of taking probiotics. This diminished 
in the third week after starting the intake of probiotics.
Migraine days
At baseline, the mean number of migraine days was 6.7±2.4 
days per month. After 4 weeks of oral intake of probiotics, 
this was 6.3±2.3 days per month, which further decreased 
to 5.1±2.2 after 8 weeks and to 5.2±2.4 migraine days 
per month after 12 weeks. In comparison to the baseline 
measurement, the number of migraine days during the 
second (5-8 weeks) and third (9-12 weeks) period were 
significant lower (P=0.008 and P=0.001, respectively). At the 
end of the intervention period, the mean number of migraine 
days per month was decreased with 1.5 days (23%) compared 
to baseline (Figure 1, individual scores from +3 migraine days 
to -5 days). Of the 27 participants, 18 participants improved 
their number of migraine days after three months compared 
with baseline, 5 participants showed no difference, whereas 
the number of migraine days was increased in 4 patients. In 
patients with gastrointestinal complaints this decrease did 
not differ significantly from those without gastrointestinal 
complaints (P>0.05, data not shown).
In 18 of the 27 participants, the number of migraine days 
per month during the last intervention period (9-12 weeks), 
was lower than the baseline number of migraine days. In 
one participant, the migraine days increased during the 
intervention period. Among the remaining participants, 
there was no difference in the amount of migraine days 
per month. In four participants, the number of migraine 
days per month was reduced with more than 50%. Mean 
migraine intensity as reported in the diaries significantly 
decreased from 6.3±1.5 at baseline to 5.5±1.9 (P=0.005).
Questionnaire outcomes
At baseline, the mean HDI score was 36.3±15.4 points. 
After 12 weeks of oral intake of probiotics, the HDI score 
decreased to 33.0±6.8 points (P=0.252). The mean MIDAS 
score decreased significantly from 24.8±25.5 points to 
16.6±13.5 points (P=0.031).
Use of medication
Except for 4 participants, every participant used migraine 
specific medication. During the intervention period, the 
use of profylaxes and triptans did not change. However, the 
use of over-the-counter analgesics (paracetamol, ibuprofen, 
aspirin) decreased from 333 dosages in weeks 1-4 to 221 in 






































Questionaire data Diary data
* *
Figure 1. Mean number of migraine days per month at baseline, 
and after 4, 8, and 12 weeks of oral intake of probiotics in 27 
migraine patients. Error bars indicate standard error of the 
mean. * indicates significant decrease compared with baseline 
(P<0.05).
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4. Discussion
In this open-label pilot study, the number of migraine days 
and migraine associated disability decreased significantly 
during 12 weeks treatment with a special designed probiotic 
mixture. Relevant adverse reactions did not occur and 
compliance was high. These findings suggest that further 
clinical studies with probiotics in migraine patients are 
feasible and warranted.
During our study, we saw a slight increase in the use of 
migraine specific medication, however, this increase 
was small and unlikely to be the cause of the decrease in 
migraine days we observed. The use of analgesics decreased 
by 29%, which is in the same range as the 23% decrease in 
migraine days we observed.
Not all participants experienced a beneficial effect of the 
probiotics. In our study, 67% of the participants showed 
a decrease in the number of migraine days, compared to 
15% who showed an increase. This is in agreement with 
other probiotic studies, were often responders and non-
responders are found (Reid et al., 2010). For instance, 
responder rates for irritable bowel syndrome are 18-80% 
(Hungin et al., 2013).
The study does not prove that the probiotic itself decreases 
migraine because a placebo effect cannot be excluded. 
However, the fact that the decrease of migraine days occurred 
not earlier than the second treatment period (5-8 weeks) and 
that this decrease continued the last treatment period (9-12 
weeks) suggests that the improvement is not due to placebo 
effects. In placebo studies, improvement during placebo 
usually starts soon after treatment and diminishes after some 
weeks of treatment (Wang et al., 2012). A meta-analysis of 
migraine prophylaxis studies showed that the placebo-effect 
(percentage of patients showing a 50% improvement) was 
22% while in our study this was at most 4/27=15% (Macedo 
et al., 2008). Placebo effects are highly dependent on the 
expectation of the participants (Elsenbruch et al., 2012), 
and we assume that participants expect stronger effects 
when they are participating in a drug trial than in a trial 
with a food supplement (de Groot et al., 2011). The lack of 
difference in probiotic treatment effect between migraineurs 
with and without gastrointestinal complaints, found in 
our study, suggests that the presence of gastrointestinal 
complaints is not a reliable selection criterion for effective 
treatment with a probiotic. A better selection criterion would 
be the presence of increased intestinal permeability. This 
can be demonstrated with different tests, like the lactulose/
mannitol test, or the use of radioisotope scanning tests 
(Scaldaferri et al., 2012). Increased intestinal permeability 
will be a selection criteria in our further studies.
Antihypertensive and antiepileptic drugs are well known 
migraine prophylaxes. They decrease migraine days with 21 
to 62% (Bussone et al., 2005; Gales et al., 2010; Holroyd et 
al., 1991; Schellenberg et al., 2008; Shuhendler et al., 2009). 
In our study, migraine days decreased with 23%, which is 
within this interval. An advantage of probiotics is the lack 
of severe side effects. In our study the well-known and 
relatively mild side effects including bloating, diarrhoea, 
constipation and nausea (D’Souza et al., 2002; Hoveyda et 
al., 2009), disappeared within three weeks of treatment.
The strength of this pilot study is that it is the first study 
using probiotics in migraine patients. However, it had 
several limitations. Next to the lack of a placebo, we did 
not measure intestinal permeability at inclusion and 
after the intervention period. Furthermore, the type of 
migraine was not classified in detail and no run-in period 
was conducted. The number of migraine days at baseline 
were based on the recall of migraine attacks per month. 
Therefore, these indications may not be as reliable as it 
could be with a run-in period. However, the number of 
migraine days at baseline was comparable with the number 
of migraine days during the first four weeks of intervention 
which suggests that baseline data were reliable. The use of 
analgesics decreased during the study. However, no baseline 
measurement of the medication use was gathered, so these 
data could not be compared with the use of medication 
before the intervention period.
Nevertheless it can be concluded that probiotics may have a 
positive influence on the severity and frequency of migraine 
and that large scale clinical randomised placebo-controlled 
studies are warranted as to evaluate working mechanisms 
and clinical efficacy. The probiotic food supplement used 
in this study may decrease migraine, both in frequency and 
intensity. This finding supports the leaky gut hypothesis. 
Feasibility and lack of adverse reactions justify further 
placebo-controlled studies.
Table 1. Total number of dosages and the mean number of dosages per participant of different categories of medicines.
 0-4 weeks 4-8 weeks 8-12 weeks
Profylaxes 297.5 (mean: 11.0) 323.5 (mean: 12.0) 302 (mean: 11.2)
Triptans 98.5 (mean: 3.6) 109 (mean: 4.0) 108.5 (mean: 4.0)
Analgesics 333 (mean: 12.3) 221 (mean: 8.2) 237.5 (mean: 8.8)
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